A Phase 1 interventional study of Cagrilintide and Semaglutide in Obesity, sponsored by Novo Nordisk A/S. Recruiting at 1 site in Denmark. Open to participants aged 50 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-05-07.
Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment
The purpose of this clinical study is to look into how study medicines CagriSema (cagrilintide and semaglutide), cagrilintide, and semaglutide affects muscle health in people with excess body weight and slightly higher than normal blood sugar as they lose weight. Participants will either get CagriSema (a new study drug), cagrilintide (a new study drug), semaglutide (a drug that doctors can already prescribe to treat people with type 2 diabetes and excess body weight) or placebo (a placebo looks like the treatment being tested but doesn't have any active ingredients in it). Which treatment participants will get is decided by chance. Participants will be in this clinical study up to 15 months.
6,296 studies on the registry are indexed under Obesity; 1,692 are open to participants now.
This study's planned enrollment of 100 is above the median of 78 across 4,878 interventional studies indexed under Obesity.
Browse Obesity studies →Novo Nordisk A/S is the lead sponsor of 1,370 studies on the registry; 102 are open to participants now.
Of its 198 completed or terminated interventional studies of FDA-regulated products, 94 (47%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion criteria
Participants will receive once weekly subcutaneous (s.c.) dose of CagriSema (cagrilintide and semaglutide) for up to 52 weeks.
Drug: Cagrilintide · Drug: Semaglutide
Participants will receive once weekly s.c. dose of semaglutide for up to 52 weeks.
Drug: Semaglutide · Drug: Placebo semaglutide
Participants will receive once weekly s.c. dose of cagrilintide for up to 52 weeks.
Drug: Cagrilintide · Drug: Placebo cagrilintide
Participants will receive once weekly s.c. dose of placebo matched to cagrilintide/semaglutide for up to 52 weeks.
Drug: Placebo cagrilintide · Drug: Placebo semaglutide
Participants will receive cagrilintide subcutaneously.
Participants will receive semaglutide subcutaneously.
Participants will receive placebo matched to cagrilintide subcutaneously.
Participants will receive placebo matched to semaglutide subcutaneously.
Change in insulin-stimulated fluorodeoxyglucose (FDG) uptake in skeletal muscle
Measured in micromoles per 100 grams per minute (μmol/100g/min).
Time frame: Baseline to Week 51
Change in insulin-stimulated FDG uptake in skeletal muscle
Measured in μmol/100g/min.
Time frame: Baseline to Week 20
Change in insulin-stimulated FDG uptake in skeletal muscle
Measured in μmol/100g/min.
Time frame: Baseline to Week 51
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Novo Nordisk A/S